NCT06396585View on ClinicalTrials.gov

The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2026

Conditions
Immunotherapy Gastroesophageal Junction
Interventions
DRUG

Tislelizumab

Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 ,Q3W

DRUG

Anlotinib

Participants will receive anlotinib,12mg, qd，d1-d14，Q3W

DRUG

Oxaliplatin

Participants will receive Oxaliplatin, 130mg/m2, iv, day 1 ,Q3W

DRUG

Tegafur

Participants will receive S-1 40-60mg/m2/c次，bid ，d1-d14，Q3W

Trial Locations (1)

350500

Fujian cancer hospital, Fuzhou

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV